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a b s t r a c t
Background: Patients with rheumatic mitral stenosis (MS) and atrial ﬁbrillation (AF) are at
risk for thromboembolism and restoration of sinus rhythm (SR) may be the preferred
strategy. Percutaneous balloon mitral valvotomy (PBMV) improves hemodynamics, but
may not be enough to restore SR.
Methods: Prospective randomized study aimed at evaluating efﬁcacy of early direct current
cardioversion (DCCV) following successful PBMV in patients with long-standing AF. Group 1
(n = 20) had patients of rheumatic MS with AF who underwent successful PBMV. Group 2
(n = 15) patients were DC cardioverted and administered oral Amiodarone for 6 weeks. Primary
endpoint was maintenance of SR after 6 months. Secondary endpoints were functional
capacity, number of embolic episodes, adverse drug effects, and all-cause mortality.
Results: In Group 2, all patients underwent successful cardioversion. At a mean follow-up of
7.6 months, 95% in Group 1 were in AF. In Group 2, 87% patients were in SR and 13% had
reverted to AF. Difference in rate of SR was 0.82 (95% CI 0.2, 1.01) ( p = 0.001), with relative risk
of 7.1 (1.95, 25.9, 95% CI, p = 0.001) for patients to be in AF who underwent only successful
PBMV, i.e. Group 1. There was signiﬁcant improvement in quality of life (SF36) score in Group
2 ( p = 0.001), with no deaths, stroke, or adverse drug effects in either group.
Conclusion: In patients with rheumatic MS and AF, early DCCV and a short-duration oral
Amiodarone, following successful PBMV, may be a reasonable strategy to attain long-term SR.
# 2016 Published by Elsevier B.V. on behalf of Cardiological Society of India.
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Rheumatic heart disease (RHD) still retains its dubious
distinction amongst the important acquired heart diseases
in developing countries, affecting young adults and account-
ing for about 25% of all patients with heart failure in endemic
countries.1 The estimated prevalence of RHD is 20 per 1000
among young adults (20–35 years), with 62–78 million
estimated cases worldwide, with 1.4 million deaths yearly
from RHD and its complications.2
Increased transmitral gradient causes raised left atrial (LA)
pressure leading to LA enlargement, causing pulmonary
venous and arterial hypertension and right-sided heart
failure.3 In addition to gradual progression, 50% patients have
episodes of acute deterioration due to paroxysmal or chronic
atrial ﬁbrillation (AF) with rapid ventricular rate, causing
pulmonary edema, acute decompensated heart failure, and
cardioembolic phenomenon.4 Persistent AF frequently com-
plicates mitral stenosis (MS) and conveys unfavorable long-
term prognosis.5–7 Over 80% patients with MS with systemic
embolism are in AF, commonest embolic site being the
cerebral circulation. High risk of thromboembolism in such
a subset of patients renders restoration of sinus rhythm (SR) to
be the preferred strategy over rate control.8
Persistent AF leads to the deleterious atrial remodeling,
which perpetuates sustenance of AF. However, it has been
seen that atrial remodeling is not a permanent phenomenon
and may be reversed. It has been proposed that relieving MS
will reduce LA dilatation, and thus may lead to reverse atrial
remodeling by changing the hemodynamics.9 Previous reports
demonstrate signiﬁcant reverse atrial electrical remodeling in
patients with MS after percutaneous balloon mitral valvotomy
(PBMV).10
PBMV or surgery is effective in relieving MS with correction
of hemodynamic alterations, but it often fails to restore SR.11 In
previous series, surgical correction of mitral valve disease
in patients with AF resulted in spontaneous conversion to
SR in 46%; however, rate of spontaneous conversion was much
lower in other reports.12 Many studies have attempted various
strategies of rhythm control in patients with rheumatic AF
after PBMV, including oral Amiodarone and direct current
cardioversion (DCCV), with varying success. However, these
studies also had a time lag between performing percutaneousFig. 1 – Flowcharttransvenous mitral commissurotomy (PTMC) and DCCV,
probably to see whether Amiodarone alone can lead to
successful pharmaco-cardioversion and to allow further
improvement in hemodynamics. These studies had indicated
that smaller LA size, shorter AF duration, and absence of
involvement of other valves were important predictors for
conversion of AF and in maintenance of SR over long term.13–16
The safety proﬁle of Amiodarone, with its interaction with oral
anticoagulants (OAC), also is a major factor which prevents its
long-term use.
No study till date has prospectively evaluated Indian
patients with severe MS of prolonged duration with enlarged
LA and long-standing AF with early DC cardioversion as a
rhythm control strategy post-PBMV. This randomized pro-
spective study was devised to evaluate efﬁcacy of early DCCV
followed by oral Amiodarone in treatment of rheumatic MS
and AF post-PBMV during the index hospitalization.
2. Material and methods
This study is a prospective randomized study performed at
AIIMS, New Delhi from January 2012 to July 2013. Ethical
approval was taken from the institutional ethical committee.
The study included patients with rheumatic MS and AF
fulﬁlling the criterion for PBMV according to American College
of Cardiology/American Heart Association guidelines.17 Other
inclusion criteria were patients above 18 years, with AF on
electrocardiogram (ECG) at least twice with minimum of 2-
week interval. Exclusion criteria were patients less than 18
years, contraindications to anticoagulation or Amiodarone
use; or requirement for surgery because of complications from
PBMV, inability to comply with 6-month follow-up, and
patients not giving written consent for participation in the
study. Patients were randomized in two groups by computer-
ized method at the time of enrollment. The ﬂow of participants
in the study is shown in Fig. 1.
Informed consent was taken from all eligible patients.
Baseline historical and clinical parameters were noted at
enrolment. Patients' functional status was assessed by New
York Heart Association (NYHA) classiﬁcation and quality of life
(QOL) was assessed by modiﬁed Medical Outcomes study
Short-form Health survey (SF-36) questionnaire (modiﬁed
for Indian population). Patients on OAC were advised to of the study.
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diography (with iE33; Philips Medical Systems, Bothell,
Washington)/transesophageal echocardiography (when need-
ed) was performed a day prior to PBMV and repeated before
DCCV. Following echocardiographic parameters were recorded
at the time of enrolment: LA size, presence of LA/LA appendage
thrombus, mean and end transmitral pressure gradient, mitral
valve area (MVA) (by pressure half-time technique/planimetry),
Wilkins' score of mitral valve, presence and severity of mitral
regurgitation (MR), to rule out severe aortic valve stenosis/
regurgitation and tricuspid regurgitation (TR), and right ventric-
ular systolic pressure from TR jet velocity.
In Group 1, patients with rheumatic MS with AF underwent
successful PBMV. PBMV was performed by transseptal ante-
grade approach using Inoue balloon technique.18,19 Appropri-
ate balloon sizing was done based on the Hung's formula.
Hemodynamic and catheterization data, including LA pres-
sure, right atrial pressure, right ventricular systolic pressure,
pulmonary artery pressure, and transmitral mean pressure
gradient, were obtained before and immediately post-PBMV.
Procedural success was deﬁned by absolute post-PBMV MVA
≥1.5 cm2 or ≥50% increase in MVA and MR not more than 2+ as
per Sellers' classiﬁcation.
In Group 2, patients, following PBMV, were loaded with
standard intravenous dose of Amiodarone (150 mg iv bolus
over 10 min) on day of PBMV followed by iv infusion of Inj
Amiodarone (1 mg/kg/min for 6 h followed by 0.5 mg/kg/min
for 18 h). The next day, these patients underwent DCCV.
Protocol for DCCV was maximum of 3 synchronized, biphasic
shocks of increasing energy of 100 J, 200 J, and 200 J, respec-
tively given under sedation with weight-based Inj Midazolam
or Propofol for sedation with biphasic cardioverter with
standard transcutaneous patches placed in antero-lateral
position in a CCU setting. In patients who failed conversion
at ﬁrst attempt, second attempt was planned at 4 weeks. Oral
Amiodarone was continued at 200 mg twice a day for 5 days
and then 100 mg once daily till 6 weeks to cover the blanking
period. Oral Amiodarone was planned to be discontinued if
patient develops side effects.
In both groups, patients were on monthly follow-up to
monitor the rhythm. ECG was done at every visit. OAC was
continued in both groups throughout the study period, with
target international normalized ratio between 2 and 3. At each
visit, patients' functional capacity and symptoms of heart
failure according to NYHA classiﬁcation and episodes of
systemic emboli were noted. The improvement in QOL was
assessed at the end of follow-up period by the SF-36
questionnaire. All patients were prospectively and intensively
monitored for side effects, including immediate and late
complications of PBMV, DCCV, and various adverse effects of
Amiodarone/OAC. Patients in both groups were administered
digoxin and other rate control drugs as per treating physicians'
discretion
2.1. Outcomes
Primary outcome measure was the rate of SR at the end of
follow period of study. Secondary endpoints were improve-
ment in functional class (NYHA), QOL, occurrence of stroke,
and death and complications of OAC/Amiodarone.2.2. Statistical analysis
Data were presented as numbers (%) or mean  SD, as
appropriate. Baseline characteristics were compared between
two groups using Chi-square test (categorical)/t-test for
independent samples (continuous) as appropriate. Primary
outcome of rate of SR/AF between groups was compared using
two samples proportions test. Changes in NYHA status was
compared between groups using Fisher's exact test. Change in
SF36 status was compared using Wilcoxon test. Hemodynamic
parameters were compared between groups using t-test for
independent samples and change from baseline within group
was tested using paired t-test. The p-value less than 0.05 was
considered as statistically signiﬁcant. Statistical analysis was
carried out using Stata 11.0 (College station, TX, USA).
3. Results
Patients were well matched for baseline characteristics in both
the groups with similar pre- and post-PBMV echocardiograph-
ic parameters, as shown in Table 1. None of the patients in
either group had development of signiﬁcant MR after PTMC.
Patients had symptomatic chronic AF for an average of 24.3
months. This duration of AF was calculated from time patients
developed symptoms associated with AF and from previous
documented ECG evidence. All patients in both groups
underwent successful PTMC with signiﬁcant improvement
in MVA (Group 1: 0.79–1.74 cm2, p = 0.001), (Group 2: 0.77–
1.82 cm2, p = 0.001) and indexed LA volume (Group 1: 55.9–
24.1 cm2, p = 0.001) and (Group 2: 66.7–29.2 cm2, p = 0.001).
At end of follow-up period (range 6–9 months), 19 patients
(95%) in Group 1 were still in AF, while 1 (5%) patient in this
group had reverted to SR spontaneously during the second
week. In Group 2, 13 (87%) patients continued to remain in SR,
while 2 patients (13%) had reverted back to AF, one at 2 weeks
and one at 4 months, as shown in Fig. 2. The difference (95% CI)
in rate of SR in both groups is 0.82 (0.2, 1.01), p = 0.0001, as
shown in Table 2. The risk for patients to be in permanent AF
who undergo only PBMV without any attempt to reversion and
maintenance of SR is 7.1 times (95% CI 1.95, 25.9), p = 0.001.
At end of follow-up, change in patient's functional status as
assessed by NYHA class was not statistically signiﬁcant ( p
value = 0.213). The QOL, as assessed by SF-36, showed similar
scores at baseline in both groups ( p > 0.05), which were
signiﬁcantly lower when compared to healthy Indian popula-
tion (data provided by earlier study).20 At 6 months, there was
improvement in scores in both groups with scores of Group 2
signiﬁcantly better ( p = 0.001–0.004), indicating better QOL in
rhythm control group, as shown in Fig. 3.
No patients were lost to follow-up. No secondary outcomes
of death, stroke, embolism, and complications related to
OACs/Amiodarone use were seen in either group.
In Group 2, post-PBMV, all patients had successful cardio-
version to SR by synchronized biphasic shocks. 8 patients
required single 100 J biphasic shock, 3 patients required 2 shocks
(1  100, 1  200 J), and 4 patients required 3 shocks (1  100,
2  200 J). There was no primary failure of DCCV.
The mean heart rate in both groups was similar on follow-
up ( p = 0.41).
Table 1 – Baseline characters of study patients (n = 35).
Variable PTMC only (n = 20) PTMC + DCCV (n = 15) p value
Age in years 33.85  12.0 37.73  9.0 0.30
Sex
Males 7 (35.0) 7 (47.0) 0.48
Females 13 (65.0) 8 (53.0)
Mean duration of symptoms in years 6.15  2.9 6.73  2.9 0.56
Duration of AF in months 23.9  8.0 24.9  7.6 0.76
Intervention in past 0.10
PTMC 3 (15.0) 2 (13.3)
Surgery 2 (10.0) 2 (13.3)
NYHA class 0.83
1 0 0
2 0 0
3 19 14
4 1 1
Preintervention drugs
Digoxin 20 (100.0) 15 (100.0) 1.00
Beta-blockers 11 (55.0) 8 (53.3) 0.07
CCBs 8 (40.0) 7 (46.7) 0.16
OAC 19 (95.0) 15 (100.0) 1.00
Diuretics 17 (85.0) 14 (93.3) 0.59
Height in cm 158.3  8.8 159.07  10.5 0.83
BMI in kg/m2 20.3  5.5 21.0  5.7 0.71
Baseline resting heart rate in bpm 96.4  7.1 98.2  6.5 0.69
Baseline mitral valve area in cm2 0.79  0.2 0.77  0.2 0.77
Mean Wilkins score 7.6  0.8 7.8  0.4 0.29
Indexed LA volume in mL 55.9  15.3 66.7  20.9 0.09
SEC 7 (35.0) 4 (26.7) 1.23
LV function % 62.25  4.4 61.3  5.5 0.59
Systolic PA pressure in mmHg 57.7  13.7 54.9  11.4 0.62
Mean transmitral gradient in mmHg on catheterization 16.6  3.4 16.5  3.4 0.93
Post-PTMC parameters
Mitral valve area in cm2 1.7  0.3 1.8  0.3 0.45
Systolic PA pressure in mmHg 39  10.3 36.3  7.8 0.41
Baseline heart rate at 4 weeks of follow-up 82.25  4.4 81.3  5.5 0.41
Indexed LA volume in mL/m2* 24.1  5.6 29.2  10.7 0.08
LV function %a 63.8  2.8 62.9  3.5 0.41
a Parameters measured at 4 weeks of follow-up.
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To the best of our knowledge, this study is the ﬁrst randomized
trial to evaluate the efﬁcacy of early DCCV along with
intravenous loading dose followed by low-dose short durationFig. 2 – Number of patients in SAmiodarone (06 weeks) in the treatment of rheumatic MS and
long-standing AF (duration >12 months) after successful
PBMV.
Long-standing AF leads to remodeling with persistent
alterations in properties and functions of atrial tissue withR during follow-up period.
Table 2 – Primary outcome of rate of SR/AF in both groups.
Follow-up at 6 months Group 1 n = 20 (%) Group 2 n = 15 (%)
Patients in AF 19 (95.0) 2 (13.0)
Patients in SR 1 (05.0) 13 (87.0)
Difference (95% CI) 0.820 (0.2, 1.01) p = 0.0001
RR (95% CI) 7.1 (1.9, 25.9) p = 0.0001
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Reduced atrial contractility, development of ﬁbrosis, and atrial
enlargement are key characteristics of atrial structural
remodeling.21 Rheumatic MS causes increased LA pressure
leading to atrial stretch.
This increase, associated with changes in refractory period
and conduction velocity, make atrial substrate conducive for
maintaining many atrial re-entry circuits leading to suste-
nance of AF. This phenomenon is associated with electrical
remodeling due to alteration in ion channel expression and
functioning. Ca2+ current inactivation and ICaL downregulation
and inward rectiﬁer K+ current enhancement decrease Ca2+
loading by reducing action potential duration. These changes
stabilize atrial reentry rotors, increasing AF vulnerability and
sustainability.10 Electrical remodeling contributes to several
clinically important phenomena, including early AF recur-
rence after cardioversion.
Cardioversion acts on atrial myocytes with irregular ﬁring
foci, by simultaneous elective depolarization and resetting the
sinus node to act as a dominant pacemaker, leading to
initiation of atrial reverse remodeling process. AF recurrence
after DCCV can be tackled by administration of antiarrhythmic
drugs to support reverse electrical remodeling. Removal of
trigger for atrial stretch by PTMC leads to hemodynamicFig. 3 – QOL assessed by SF-36 at Baseline and after 6 months. PF
health problems; BP – bodily pain; GH – general health; VT – vit
emotional problems; MH – mental health.changes, which initiate atrial structural reverse remodeling.11
Decrease in LA volume and mean LA pressure accompanied by
shortening of p wave duration were observed after PBMV,
indicating the process of reverse electrical and structural
remodeling, which reduced the vulnerability for occurrence of
sustained AF.
Hemodynamic parameters in both groups (pre- and post-
PBMV) have been comparable, suggesting that PTMC alone
does not signiﬁcantly cause spontaneous cardioversion to
SR. LA indexed volume was signiﬁcantly reduced at 6
months, as compared with baseline in both groups, indicat-
ing that reduction in LA dimension after successful PBMV
helps to maintain SR but is not sufﬁcient for reverting long-
standing AF to SR, and additional measures should be taken
to restore SR.
Amiodarone was continued in low doses for short term only
to facilitate early electrical reverse remodeling. PBMV followed
by early DCCV, along with short-duration antiarrhythmic use
in patients with long-standing AF, may cause simultaneous
electrical and structural reverse atrial remodeling and thus
beneﬁts cardioversion of AF and maintenance of SR over
longer duration. Our study showed that short-duration
Amiodarone was well tolerated with no adverse effects
necessitating discontinuation of treatment. Discontinuation – physical functioning; RP – role limitations due to physical
ality, energy and fatigue; SF – social functioning; RE –
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during the follow-up period.
In the study by Hu et al., 96% patients maintained SR on
continued low-dose Amiodarone therapy (100–200 mg/day,
mean maintenance dose of 130 mg/day at 24 weeks and
121 mg/day at 52 weeks) for a duration of 1 year (with side
effects including thyroid abnormalities despite low dose).
Another trial, which evaluated patients of AF with RHD,
including multivalvular involvement and post-operative cases
with rhythm control strategy by DCCV, showed that a
conversion rate to SR was around 85%, of which only 52%
patients maintained SR at 1 year despite long-term Amiodar-
one therapy.14 In another study, when DCCV was attempted at
one month after PBMV, while on oral Amiodarone, successful
DCCV was achieved only in 71% patients and AF recurred in
48% patients on follow-up despite long-term Amiodarone.15
This study also documented adverse effects of long-term oral
Amiodarone. In this study, an early DCCV followed by oral
Amiodarone, as in our study, led to a better conversion to SR
and maintenance of SR in Group 1 suggesting a greater role of
an early DCCV. This translated into lesser hospital and patient
costs by allowing early discharge and avoiding readmission for
DCCV at a later date.
Our study showed that maintenance of SR lead to better
functional class as seen by improvement in NYHA class
(however, statistically NS p > 0.05). The QOL as assessed by
SF36 showed signiﬁcant improvement in patients with SR, as
compared to the PTMC-only group ( p = 0.001–0.004). During
the follow-up period, no cardioembolic events were noted in
both groups, neither any adverse effects of OAC occurred. This
ﬁnding may be confounded because period of follow-up was
short and patients were still on OACs.
We, hereby, demonstrated that electrical and structural
reverse remodeling can be initiated successfully simulta-
neously, by performing PBMV followed by DCCV within a short
interval. This may be important in developing countries where
patients may not have facility for repeated or prolonged
hospitalization.
The beneﬁts of maintenance of SR in rheumatic MS with AF
are improvement in ventricular function by reversing atrial
cardiomyopathy, prevention of blood stasis in LAA and LA,
thus preventing thrombus formation, and reduction in
cardioembolic complications.18 Short duration of antiarrhyth-
mic drug therapy reduces complications associated with
administration of long-duration antiarrhythmics. Amiodarone
has signiﬁcant long-term toxic effects and drug interactions
with OAC, digoxin, etc., and it may be safer to discontinue this
drug as soon as possible.
The limitation of our study is small numbers of patients
and short follow-up. Also, we did not study occurrence of
paroxysmal AF in study groups since it was not part of our
protocol.
5. Conclusion
In patients with rheumatic MS with AF, after successful
PBMV, it is possible to achieve and maintain SR by an early
DCCV and short-term antiarrhythmic drug administration.
Patients beneﬁted from restoration and maintenance of SRdemonstrated by improvement in functional class and
improvement in QOL. Early rhythm control by DCCV should
therefore be considered as a feasible and safe therapy for
patients with rheumatic MS with long-standing AF after
PBMV. In addition to the clinical beneﬁts, early DCCV strategy,
by doing away with readmissions, not only decreases the cost
but also adds to the convenience.
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